SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

12 Feb 2025 Evaluate
The Total revenue for the quarter ended December 2024 of  Rs. 12.08 millions grew by 5652.38% from Rs. 0.21 millions.The Net Loss for the quarter ended December 2024 is Rs. -15.94 millions as compared to Net Loss of Rs. -16.34 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 improved to -17.26% as compared to -21.96% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 12.08 0.21 5652.38 22.08 0.21 10414.29 0.28 0.00 0.00
Other Income 0.04 -9.01 -100.44 0.12 -7.87 -101.52 7.95 0.00 0.00
PBIDT -17.26 -21.96 -21.40 -45.64 -47.10 -3.10 -55.76 -98.91 -43.63
Interest 0.70 0.00 0.00 0.96 0.01 9500.00 3.33 0.00 0.00
PBDT -17.96 -21.96 -18.21 -46.60 -47.11 -1.08 -59.09 -98.91 -40.26
Depreciation 0.50 0.14 257.14 1.48 0.31 377.42 1.77 0.17 941.18
PBT -18.46 -22.10 -16.47 -48.08 -47.42 1.39 -60.86 -99.08 -38.57
TAX -2.52 -5.76 -56.25 -5.83 -12.65 -53.91 -11.37 -23.52 -51.66
Deferred Tax -2.52 -5.76 -56.25 -5.83 -12.65 -53.91 -11.37 -23.52 -51.66
PAT -15.94 -16.34 -2.45 -42.25 -34.77 21.51 -49.49 -75.56 -34.50
Equity 352.68 214.44 64.47 352.68 214.44 64.47 352.68 214.44 64.47
PBIDTM(%) -142.88 -10457.14 -98.63 -206.70 -22428.57 -99.08 -19914.29 0.00 0.00

Pharmaids Pharma Share Price

30.92 -0.49 (-1.56%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×